Abstract
Introduction
Blood vessel formation in adults may proceed through various pathways. The primary mechanism is angiogenesis by either sprouting or intussusception, both being vascular endothelial growth factor (VEGF)-dependent processes [1, 2] . In addition, a VEGF-independent mechanical or looping angiogenesis has been described [3] . Vasculogenesis, previously regarded to be exclusively involved in vessel formation in the embryo, has also been shown to contribute to vessel formation in adults. This process involves the recruitment of endothelial progenitor cells (EPC) released from the bone marrow and incorporated into growing vessels in adults [1, 4] . The molecular characteristics and the isolation of these cells are still a matter of debate [5] .
The most commonly used EPC markers are CD34, vascular endothelial cell growth factor receptor 2 (VEGF-R2/Flk-1), Tie2, stem cell antigen-1 and CD133 (AC133). However, none of these molecules is specific for EPC [5, 6] . Because of their low abundance (0.01 to 0.0001%), the isolation of EPC is technically difficult [5] . In addition, mature endothelial cells, probably released from vessel walls, circulate in the peripheral blood and share common markers with the EPC [5, 6] . A large body of evidence indicates that EPC contribute to the formation of new vessels upon vascular injury, chronic inflammatory, hypoxic conditions and tumour growth [7] [8] [9] [10] .
In the rheumatic autoimmune disorders rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), reduced numbers of circulating EPC have been described [11] [12] [13] [14] . In RA, these cells display impaired migratory capabilities [13] , possibly contributing to endothelial dysfunction associated with the increased cardiovascular morbidity and mortality commonly observed in these patients [15] . The [19] . [20] [21] [22] [23] [24] . [25] and mediates the potent anti-angiogenic effects of these cytokines, both in vitro and in vivo [26] [27] [28] . It inhibits endothelial cell proliferation, migration and invasiveness in vitro [26] [27] [28] . The anti-angiogenic effect of GBP-1 has recently been confirmed in colorectal carcinoma patients, where it was associated with sustained reduction of intratumoral angiogenic activity and improved cancer-related survival [29] . Interestingly, GBP -1 [30] .
molecular mechanism of EPC dysfunction is elusive. It has been suggested that chronic inflammation and increased levels of the pro-inflammatory cytokines interferon (IFN)-␣/␥, tumour necrosis factor (TNF)-␣ or interleukin (IL)-1␣/␤ [16-18] may be involved in this process. This was partly confirmed by the finding that anti-TNF-␣ treatment restored EPC levels in RA patients

Guanylate binding protein-1 (GBP-1) is a member of the family of large GTPases, which includes antiviral Mx proteins and the caveolae regulatory molecule dynamin
GBP-1 expression is induced in endothelial cells by IFN-␥/-␣, IL-1␤/-␣ and TNF-␣
was described as the first GTPase secreted from endothelial cells. Secretion occurs via non-classical secretion pathways and was confirmed in vivo by the detection of increased GBP-1 concentrations in the cerebrospinal fluid of patients with bacterial meningitis
Here we show that the levels of GBP-1 are increased in sera of patients with the rheumatic autoimmune diseases RA, SLE and SSc, which are characterized by chronic inflammatory vessel activation. We provide experimental evidence that GBP-1 is directly involved in the endothelial dysfunction and the regulation of EPC activity. 
Materials and methods
Patient characteristics
Cell culture and stable transfection
T17b murine embryonic EPC [34, 35] 
Wound-healing assay
The wound-healing assay was performed as described previously [28] . 
RNA isolation and RT-PCR
RNA isolation and RT-PCR was performed as previously described [24] . 
Western blot
Western blotting of Ripa cell lysates was performed as described previously [25, 30] 
Immunocytochemistry
Immunocytochemistry was performed as previously described [37] . 
Differentiation of control-and GBP-1-EPC
Differentiation of EPC was induced by the application of differentiation medium (DM) containing retinoic acid and cyclic adenosine monophosphate (cAMP) on four consecutive days following a previously described
protocol [34] . In brief, the DM was generated by supplementing normal medium with 0. 
GBP-1-ELISA
Generation of the AV-loop
Operations were performed as previously described [38] [39] [40] 
Histological analysis
The animals were perfused with Microfil prior to explantation of the constructs. The abdomen was opened via a midline incision, and the aorta and inferior vena cava were exposed. [25] . In this framework it was interesting that impaired functions of circulating EPC have been described in patients with rheumatic autoimmune disorders [11] [12] [13] [14] [26] [27] [28] (Fig. 2A, GBP-1) were selected and pooled for further studies. The cell population obtained showed a purity of more than 95% when GBP-1 expression was analysed at the single cell level by immunocytochemistry (Fig. 2B, GBP-1 (Fig. 2A) or immunocytochemistry (Fig. 2B) . Culture supernatants showed significantly elevated GBP-1 concentrations in GBP-1-transfected cells by ELISA (Fig. 2C, left) . Cell lysis was not increased under these conditions, as shown by the quantification of lactate dehydrogenase in the same supernatants (Fig. 2C, right) . The amount of GBP-1 present in the supernatant of GBP-1-EPC was similar to the amount previously described to be actively secreted from IFN-␥-stimulated HUVEC within the same period of time [30] .
Results
Sera levels of GBP-1 are increased in patients with systemic autoimmune diseases
GBP-1 induces premature differentiation of EPC
GBP-1 expression in tissues is closely associated with endothelial cells
. Therefore, we aimed to investigate the function of GBP-1 in EPC. GBP-1 cDNA was stably expressed in the murine endothelial embryonic progenitor cell line T17b in order to investigate the role of GBP-1 in a well-defined experimental model for EPC. Three cell clones, which exhibited GBP-1 expression levels similar to those observed in IFN-␥-treated human endothelial cells
pool). The control cells (control-EPC) stably transfected with the empty vector did not show any signal in analyses by Western blotting
These results indicated that EPC similarly as differentiated endothelial cells secrete GBP-1, which may contribute to increased serum concentrations of this protein in patients with rheumatic autoimmune disorders.
Differentiation of T17b cells can be induced by treatment with cAMP and retinoic acid [34] . Analysis by immunocytochemistry showed that the induction of differentiation did not affect GBP-1 expression levels in these cells (Fig. 3A, compare (Fig. 3A) . (Fig. 3B, right part [ϩ] ). GBP-1 expression was not altered by treatment with cAMP and retinoic acid (Fig. 3B) , and GAPDH levels demonstrated that equal amounts of RNA had been loaded (Fig. 3B) [30] in serum samples of patients suffering from RA (n ϭ 50), SLE (n ϭ 51), SSc (n ϭ to that observed after standard treatment for differentiation (Fig. 3 (Fig. 4A) . Moreover, time-course analysis employing the woundhealing assay showed that migration of GBP-1-EPC was significantly inhibited compared to control-EPC (Fig. 4B) . The results obtained after 10 hr incubations clearly demonstrate the reduced capability of GBP-1-EPC to recultivate the wounded areas (Fig. 4C) . (Fig. 5A, FC) . A fibrovascular tissue sheath (Fig. 5A, T (Fig. 5B) . In contrast, at the largest distance (Ͼ135 m), cell densities of GBP-1-EPC and control-EPC were not statistically different (Fig. 5B) . Representative histological pictures demonstrate this fact (Fig. 5C) . GBP-1-EPC showed a clearly reduced capability to immigrate into the fibrovascular sheath towards increasing oxygen concentrations compared with control-EPC (Fig. 5C, compare GBP-1 [44, 45] .
The same phenotypical changes (enlargement and reduced number of cells) were observed in differentiated control cells in the absence of GBP-1 expression (data not shown). It has been shown that differentiation of T17b cells increases the expression of vascular endothelial growth factor receptor 2 (VEGF-R2/Flk-1) and vWF [34]. This was confirmed by RT-PCR in control cells after treatment with cAMP and retinoic acid (Fig. 3B, left part, compare [-] and [ϩ] differentiation). Interestingly, in cells stably expressing GBP-1, the expression of both factors was increased to similar levels in the absence of cAMP and retinoic acid (Fig. 3B, right part, [-]) In line with this observation, expression levels of both factors were slightly up-regulated in GBP-1-transfected cells upon treatment with cAMP and retinoic acid
. Quantitative evaluation of the results confirmed that induction by GBP-1 of both vWF and Flk-1 expression was similar
Fig. 1 GBP-1 levels are increased in sera of patients with the autoimmune diseases, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or systemic sclerosis (SSc). GBP-1 was quantified by ELISA
92) and NHD (n ϭ 80). A vertical scatter plot is given with a line corresponding to the mean values. A dashed line indicates the mean of the NHD plus two standard deviations. A t-test for independent samples was used to determine significance (asterisks given for P-values Ͻ 0.05). Non-detectable (n.d.) indicates GBP-1 values below the detection limit of the ELISA.
Fig. 2 Detection of GBP-1 expression and secretion in stably transfected EPC. (A) Western blot analysis of total cell lysates obtained from EPC clones stably transfected with control-vector pMCV-2.2 (control-EPC) or with flagtagged GBP-1 (GBP-clones 1, 2 and 3). Immunochemical detection of actin demonstrates equal protein loading. (B) Control-and GBP-1-EPC were stained by immunocytochemistry for GBP-1 using a monoclonal rat antihuman GBP-1 antibody (clone 1B1) and an Alexa488-labelled secondary antibody. GBP-1-staining is visualized by green colour. Counterstaining was performed with DAPI (blue). (C) Extracellular GBP-1 was quantified in the culture supernatants of control-and GBP-1-EPC by ELISA. Non-specific leakage of intracellular proteins was estimated by quantification of lactate dehydrogenase activity (U/L) in the cellular
GBP-1 inhibits proliferation and migration of EPC in vitro
The proliferative and migratory behaviours of control-and GBP-1-EPC were investigated to evaluate whether GBP-1 expression impaired the EPC phenotype. Proliferation of GBP-1-EPC was significantly (P Ͻ 0.05) inhibited compared to control-EPC
GBP-1 inhibits the migration of embryonic EPC in vivo
The migratory potential of the GBP-1-expressing and GBP-1-nonexpressing T17b cells in vivo was studied in the AV-loop model of
Fig. 3 After in vitro differentiation, GBP-1 expression is stably maintained and promotes EPC differentiation. (A) Staining of undifferentiated (Undiff.) and differentiated (Diff.) GBP-1-EPC by immunocytochemistry was performed with a rat anti-human GBP-1 antibody (green). Counterstaining was performed with DAPI (blue). (B) Semi
GBP-1 inhibits endothelial cell proliferation, migration and invasion [26] [27] [28] , and inhibiting its expression abrogates these effects in endothelial cells exposed to inflammatory cytokines [16] [17] [18] 
